CSRxP Urges E&C Lawmakers to Continue Building Bipartisan Consensus

Sep 23, 2019

Hearing on Drug Pricing Proposals an Opportunity for Focus on Areas of Agreement to Hold Big Pharma Accountable and Lower Drug Prices 

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) released a statement Monday ahead of a U.S. House Committee on Energy and Commerce Subcommittee on Health hearing Wednesday titled “Making Prescription Drugs More Affordable: Legislation to Negotiate a Better Deal for Americans.”

“The plans put forward by Speaker Pelosi and Senators Grassley and Wyden both reflect key reforms with broad bipartisan support, including measures to reform the Medicare Part D program by giving Big Pharma more skin in the game, capping out-of-pocket costs and keeping price hikes below the rate of inflation,” said CSRxP executive director Lauren Aronson. “We encourage lawmakers, in both parties, to use every opportunity, including the hearing Wednesday, to focus on areas of agreement and continue building bipartisan consensus to hold Big Pharma accountable and lower prescription drug prices.”

“We applaud lawmakers for their continued, bipartisan commitment to holding Big Pharma accountable and lowering prescription drug prices,” Aronson continued. “Big Pharma is responsible for setting and hiking list prices and lawmakers simply must capitalize on the unprecedented momentum to hold the industry accountable for its egregious practices.”

Read more on CSRxP’s take on the drug pricing package put forward by Speaker Pelosi HERE.

Read more on CSRxP’s take on the Senate Finance drug pricing package HERE.

Read more on additional market-based solutions to hold Big Pharma accountable and lower drug prices HERE.